Motor Neuron AAV Reprogramming to Delay ALS Degeneration

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Amyotrophic lateral sclerosis (ALS) is characterized by motor neuron degeneration, with aging increasing susceptibility to the disease, as transcription factors Islet1 and Lhx3 are downregulated postnatally, necessitating a method to reactivate these factors to prevent degeneration.

Innovation Solution

Administering adeno-associated viruses (AAVs) encoding enhancer sequences and transcription factors like Isl1 and Lhx3 to drive motor-neuron specific expression, rejuvenating neurons and enhancing resistance to ALS pathogens.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If transcription factors Isl1 and Lhx3 are downregulated in postnatal motor neurons, then motor neurons become susceptible to ALS, but reactivating embryonic transcription factors in postnatal neurons is challenging

Engineering Contradiction:

Improvemotor neuron resistance to ALSVSAvoidcomplexity of reactivation method

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent uses adeno-associated viruses (AAVs) as intermediary vectors to deliver transcription factor genes into postnatal motor neurons. The AAVs serve as a mediator that enables the reactivation of embryonic transcription factors (Isl1 and Lhx3) in adult neurons without requiring direct genetic manipulation of the neurons themselves, thus resolving the contradiction between achieving reactivation and maintaining system simplicity

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent employs enhancer sequences that are预先 designed to drive transcription factor expression specifically in motor neurons. These enhancers are prepared in advance and incorporated into the AAV vectors before administration, ensuring that once the viruses infect the neurons, the transcription factors are immediately and specifically expressed without requiring additional complex activation steps

Inventive Principle:

Principle #10Preliminary action

2Manufacturing precision

If AAVs are used to deliver transcription factors, then motor neuron specific expression is achieved, but delivery efficiency and specificity must be optimized

Engineering Contradiction:

Improvemotor neuron specific expressionVSAvoidease of AAV delivery

Core Design Contradiction:

Manufacturing precisionVSEase of manufacture

Solution Approach 1:

The patent incorporates motor neuron-specific enhancer sequences into the AAV vectors to ensure that transcription factor expression is localized specifically to motor neurons rather than being expressed throughout the entire nervous system. This local quality approach allows the same AAV delivery system to achieve high specificity without requiring different delivery methods for different cell types

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent optimizes various parameters of the AAV system including viral titer, injection dosage, and enhancer sequence design to balance delivery efficiency with expression specificity. By adjusting these parameters, the system achieves effective gene delivery while maintaining precise control over where and how much transcription factor is expressed

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20250339563A1Re-expression of embryonic motor neuron transcription factors in post-natal animals as a therapeutic strategy for amyotrophic lateral sclerosis

Publication Date: 2025.11.06 THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK

AI summary

The subject matter described here relates to methods, compositions, and vectors for treating Amyotrophic Lateral Sclerosis (ALS) in a subject in need thereof. In certain aspects, the method comprises administering to the subject a composition comprising adeno-associated viruses (AAVs), wherein the AAVs comprise a nucleic acid sequence comprising an enhancer sequence and encoding one or more transcription factors that control gene expression in nascent motor neurons, wherein the enhancer is capable of driving a motor-neuron specific expression of the one or more transcription factors and wherein the one or more transcription factors are expressed in motor neurons of the subject.